DTC
Deep Track Capital Portfolio holdings
AUM
$3.11B
1-Year Return
13.6%
This Quarter Return
+37.62%
1 Year Return
+13.6%
3 Year Return
+265.73%
5 Year Return
–
10 Year Return
–
AUM
$2.29B
AUM Growth
+$270M
(+13%)
Cap. Flow
-$39M
Cap. Flow
% of AUM
-1.7%
Top 10 Holdings %
Top 10 Hldgs %
46.99%
Holding
74
New
13
Increased
16
Reduced
22
Closed
16
Top Buys
| 1 |
Insmed
INSM
|
$85.2M |
| 2 |
Biogen
BIIB
|
$83.1M |
| 3 |
Sarepta Therapeutics
SRPT
|
$68.4M |
| 4 |
Ionis Pharmaceuticals
IONS
|
$45.5M |
| 5 |
AUTL
Autolus Therapeutics
AUTL
|
$28.5M |
Top Sells
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$110M |
| 2 |
NovoCure
NVCR
|
$98.3M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
$56.8M |
| 4 |
Kura Oncology
KURA
|
$43.5M |
| 5 |
Fate Therapeutics
FATE
|
$29.4M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Edgewise Therapeutics
EWTX
$1.65B
| $30.2M | 1.27% |
3,374,394
| – | – |
|
|
SLN
27
Silence Therapeutics
SLN
$262M
| $29.8M | 1.25% |
1,951,580
| – | – |
|
|
AUTL
28
Autolus Therapeutics
AUTL
$378M
| $28.5M | 1.2% |
+15,000,000
| New | +$28.5M |
|
29
Astria Therapeutics
ATXS
$413M
| $27M | 1.14% |
+1,816,531
| New | +$27M |
|
|
VIGL
30
DELISTED
Vigil Neuroscience
VIGL
| $26.3M | 1.1% |
2,104,174
-259,014
| -11% | -$3.24M |
|
31
RAPT Therapeutics
RAPT
$211M
| $25.8M | 1.08% |
+163,118
| New | +$25.8M |
|
32
Esperion Therapeutics
ESPR
$534M
| $24.9M | 1.05% |
4,000,000
-1,636,587
| -29% | -$10.2M |
|
33
Nurix Therapeutics
NRIX
$742M
| $24.9M | 1.04% |
2,266,569
+212,948
| +10% | +$2.34M |
|
34
Dynavax Technologies
DVAX
$1.18B
| $24.8M | 1.04% |
+2,327,951
| New | +$24.8M |
|
35
Intellia Therapeutics
NTLA
$1.27B
| $24.4M | 1.03% |
700,000
+400,000
| +133% | +$14M |
|
36
Acumen Pharmaceuticals
ABOS
$87.2M
| $21.3M | 0.9% |
3,952,000
+173,182
| +5% | +$935K |
|
|
37
BioMarin Pharmaceuticals
BMRN
$11.1B
| $19.6M | 0.82% |
189,800
-549,063
| -74% | -$56.8M |
|
38
Crinetics Pharmaceuticals
CRNX
$3.3B
| $19.2M | 0.81% |
1,048,829
-4,171
| -0.4% | -$76.3K |
|
39
Geron
GERN
$900M
| $17.9M | 0.75% |
+7,414,693
| New | +$17.9M |
|
40
Heron Therapeutics
HRTX
$202M
| $16.2M | 0.68% |
6,496,976
-2,051,411
| -24% | -$5.13M |
|
41
Nuvation Bio
NUVB
$1.37B
| $15.8M | 0.66% |
8,221,188
-1,104,352
| -12% | -$2.12M |
|
42
Syndax Pharmaceuticals
SNDX
$1.46B
| $12.7M | 0.53% |
+500,000
| New | +$12.7M |
|
43
Relmada Therapeutics
RLMD
$54.1M
| $9.9M | 0.42% |
2,837,818
+2,376,957
| +516% | +$8.3M |
|
44
Protagonist Therapeutics
PTGX
$3.7B
| $9.51M | 0.4% |
+871,493
| New | +$9.51M |
|
45
Nkarta
NKTX
$156M
| $8.11M | 0.34% |
1,354,200
-1,460,644
| -52% | -$8.75M |
|
46
Avidity Biosciences
RNA
$6.43B
| $6.66M | 0.28% |
+300,000
| New | +$6.66M |
|
47
Viking Therapeutics
VKTX
$2.97B
| $5.73M | 0.24% |
+610,083
| New | +$5.73M |
|
48
Fulcrum Therapeutics
FULC
$418M
| $5.6M | 0.23% |
768,607
-132,104
| -15% | -$962K |
|
49
GH Research
GHRS
$876M
| $4.85M | 0.2% |
499,400
| – | – |
|
|
JNCE
50
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $4.73M | 0.2% |
4,259,653
| – | – |
|